Cancer is a fatal disease, and most patients die from it today because there are no symptoms in the early stages of the disease. At the European Cardiology Congress, iBiopsy presented new results on the performance of their Lung Cancer Screening Software as Medical Device. By integrating more patients into their system, they reached a sensitivity of 96.5% and specificity of 97.2% in the detection of cancerous lung nodules. They are now able to analyze a medical image’s signal to find the signal that corresponds to lung cancer, liver cancer, breast cancer, and more using artificial intelligence. The AI allows correlation of the image’s signal with patient information to make a diagnosis, and iBiopsy was able to eliminate almost all false positives. The company has 20 years of experience and understanding of cancer, which led to their ability to drive their system in the right direction. They worked with the history of over 1,700 patients and more than 17,000 lung nodules over 20 years, making it possible to verify whether their predictions were correct or not. They were able to detect nodules and tell if they were malignant or benign. This breakthrough is significant because it means that they can set up a large-scale screening plan to diagnose potential cancer in a preventive way via a simple non-invasive scan and without surgery.
AI and the Paradigm Shift for Early Cancer Diagnosis (Part I) – MedicalExpo e-Magazine.
French company, Median Technologies, showcased their revolutionary technology at the 2023 European Congress of Radiology. This technology combines medical imaging and artificial intelligence to diagnose various types of cancers at an early stage, which can lead to the emergence of new therapies that cater to the individual patient. The medical imaging platform, iBiopsy®, integrates AI and machine learning technologies, which allows the development of software as medical devices to detect and characterise cellular information from CT images or other imaging modalities that cannot be seen by the naked eye.
New results presented at the ECR revealed the performance of the iBiopsy® Lung Cancer Screening (LCS) Software as Medical Device, which can determine if a lung tumor found in a patient is cancerous or not with a 96.5% sensitivity and 97.2% specificity. In an interview with Fredrik Brag, CEO and founder of Median Technologies, he spoke about how this technology is a real “paradigm shift” for early cancer diagnosis.
When asked about the company and their main areas of technological development, Brag stated that Median Technologies deploys proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services to better manage life-threatening diseases such as cancer. The technologies transform medical images into decisional insights to better diagnose, treat, and monitor patients.
Revolutionizing Cancer Treatment and Diagnosis with AI and Medical Imaging
Median Technologies, a French company that specializes in medical imaging and artificial intelligence (AI), has developed a revolutionary technology that combines both to diagnose many types of cancers early. The company’s iBiopsy® medical imaging platform integrates AI and machine learning technologies, allowing the development of software as medical devices to detect and characterize cellular information from CT images or other imaging modalities that cannot be seen by the naked eye.
Partnership with INRIA
Median Technologies was launched 20 years ago through a collaboration with INRIA, the French National Institute for Research in Computer Science and Control. INRIA is one of the best computer science and artificial intelligence research laboratories in the world, with significant contributions to satellite image and missile guidance for the army.
Two Areas of Focus
Median Technologies has two areas of focus:
- Working with pharmaceutical companies to better develop new cancer treatments, understand the mechanism of action of these new drugs, and ultimately propose targeted treatments for patients. The company’s technology, used in oncology clinical trials, allows analysis of whether the patient is really responding to treatment or not. Median Technologies currently manages nearly 220 clinical studies for major pharmaceutical companies in oncology, both in immuno-oncology and in targeted therapy.
- Developing the “diagnosis of the future”, which is the new generation of diagnostics. These are non-invasive diagnostics based on medical images, where an intervention or a biopsy is not necessary to understand what is going on. These are diagnostics that need to be readily available to everyone, much like mammograms for breast cancer screenings in women.
Importance of Early Diagnosis
Diagnosing cancer in its early stages is critical to achieving successful treatment outcomes. Median Technologies CEO and founder, Fredrik Brag, emphasized that the mortality rate of lung cancer is 94% at 5 years if the disease is diagnosed at an advanced stage, compared to a survival rate of 92% at 15 years if it is diagnosed at an early stage. Median Technologies’ iBiopsy® Lung Cancer Screening (LCS) Software as Medical Device can determine if a lung tumor found in a patient is cancerous or not with a 96.5% sensitivity and 97.2% specificity, making it a crucial tool in the fight against cancer.
Through its innovative technology, Median Technologies aims to transform medical images into decisional insights to better diagnose, treat, and monitor patients, contributing to a paradigm shift in early cancer diagnosis and personalized medicine.
Virtual Biopsies with AI-Powered iBiopsy®
Traditional biopsies are often invasive, painful, and expensive, making it infeasible to perform biopsies on everyone to determine whether a tumor is cancerous or not. That’s where Median Technologies’ iBiopsy® comes in, offering a virtual biopsy by image from a simple scanner.
iBiopsy® at the European Cardiology Congress
At the European Cardiology Congress, Median Technologies presented new results on the performance of their iBiopsy® Lung Cancer Screening Software as Medical Device. On a cohort of 9,863 patients, the software demonstrated a sensitivity of 96.5% and a specificity of 97.2% in characterizing cancerous lung nodules. These impressive results highlight the potential of iBiopsy® in detecting cancer at an early stage and increasing the chances of successful treatment.
Analyzing the Signal of Medical Images with AI
iBiopsy® works by analyzing the signal of a medical image, such as a CT or MRI scan, using artificial intelligence to identify signals that correspond to lung cancer, liver cancer, breast cancer, and more. While radiologists can see anatomical information with the naked eye, they cannot see cellular or genetic levels or determine whether a structure is fibrotic or a tumor, or whether it is malignant or benign.
Revolutionizing Cancer Diagnosis
By analyzing medical images with AI, iBiopsy® aims to transform medical images into decisional insights, leading to better diagnosis, treatment, and monitoring of patients. With the potential to replace invasive biopsies and identify cancer at an early stage, iBiopsy® offers a more feasible and accessible approach to cancer diagnosis.
Virtual Biopsies: The Future of Cancer Diagnosis
The iBiopsy® technology represents a significant shift in cancer diagnosis, offering a more accessible and less invasive approach to detecting cancer at an early stage. With the potential to transform the future of cancer diagnosis and treatment, iBiopsy® provides hope for patients and healthcare professionals alike.
How AI Revolutionizes Cancer Diagnosis
Cancer is a disease that claims many lives worldwide due to the difficulty of diagnosing it in its early stages. Most patients die from cancer because symptoms are not noticeable in the early stages of the disease, and diagnosis comes too late. However, a new technology called iBiopsy® Lung Cancer Screening Software as Medical Device is revolutionizing cancer diagnosis by identifying what is not seen by the naked eye, and doing it with the help of artificial intelligence (AI).
The Problem with Traditional Imaging
The current traditional imaging that radiologists use is limited to showing anatomical information in the image, but it fails to provide more in-depth cellular or genetic-level data. This results in false positives, making it challenging for health systems to manage. The radiologist relies on visual acuity to make a diagnosis, but this method is not giving them the information they need.
The Solution: iBiopsy® and Artificial Intelligence
The iBiopsy® software uses AI to analyze signals from medical images, such as CT or MRI scans. By using AI, the software can determine what the radiologist cannot see with the naked eye. The AI correlates information from different sources, such as a signal on the image with information about the patient, and makes a diagnosis based on that information.
The Benefits of iBiopsy®
With the help of AI, iBiopsy® can diagnose cancer in its early stages. It achieves this by identifying cellular information behind an image, such as lung nodules, and determining if they are malignant or benign. By doing this, the software can detect cancer with a sensitivity of 96.5% for a specificity of 97.2%. The iBiopsy® software is non-invasive, and unlike traditional biopsy methods, it is not painful or expensive, making it accessible to everyone.
The Role of Clinical Understanding in AI
The success of iBiopsy® is not just about the algorithms but also the clinical understanding of the disease. The developers of iBiopsy® have been working with the largest cancer centers in the world in Europe, the United States, and Asia. They have trained their system on a range of data, but they also have clinical and scientific knowledge of the disease to understand what they’re analyzing and how AI can provide an answer.
Conclusion
The iBiopsy® Lung Cancer Screening Software as Medical Device is revolutionizing cancer diagnosis. By using AI, iBiopsy® can identify what is not seen by the naked eye, diagnose cancer in its early stages, and provide a non-invasive alternative to traditional biopsy methods. The clinical and scientific knowledge behind iBiopsy® makes it a reliable and accessible option for cancer diagnosis, and a promising tool in the fight against cancer.
Revolutionizing Early Cancer Diagnosis with AI
Cancer is a deadly disease, and the main reason patients die from it today is that there are often no symptoms in the early stages. By the time symptoms appear, the disease is already advanced, making curative treatments less effective. Traditional biopsies can be extremely painful and expensive, making it impossible to perform them for everyone. This is where iBiopsy® comes in, a virtual biopsy performed through a simple scanner, developed by Median Technologies.
The Limitations of Visual Acuity
In the case of a CT or MRI scan, the radiologist relies on visual acuity to make their diagnosis. However, radiologists are unable to see the cellular or genetic levels, and cannot tell with the naked eye if what they are looking at is a fibrotic structure or a tumor, and whether it is malignant or benign. This generates many false positives, making the job of radiologists difficult.
The iBiopsy® Solution
iBiopsy® analyzes the signal of a medical image using artificial intelligence to understand what the signal of the image means and find the signal that corresponds to different types of cancer. The system correlates the signal from the image with other information concerning the patient, such as the result of a biopsy, to determine what the patient has or does not have. This AI solution is not limited to anatomical information but can identify what is not seen by the naked eye.
Exceptional Performance Rates
In a study presented at the European Cardiology Congress, Median Technologies demonstrated the exceptional performance of their iBiopsy® Lung Cancer Screening Software as Medical Device. The study was conducted on a cohort of 9,863 patients, and the results showed that the characterization of cancerous lung nodules reached a sensitivity of 96.5% for a specificity of 97.2%. This surpassed giants like Google in terms of sensitivity and specificity, even though Google has much larger AI teams. Median Technologies’ 20 years of experience and understanding of cancer is what allowed them to drive their system in the right direction, achieving high performance rates.
A Large-Scale Screening Plan
In a previous study, Median Technologies worked with the history of 1,760 patients over 20 years and more than 17,000 lung nodules to create a large-scale screening plan. This plan is available to everyone via a simple non-invasive scan and without surgery, to diagnose potential cancer in a preventive way. The iBiopsy® system is able to detect nodules and tell if they are malignant or benign, making it an effective tool for early cancer diagnosis.
A Paradigm Shift in Early Cancer Diagnosis
The exceptional performance rates achieved by iBiopsy® have led to a paradigm shift in early cancer diagnosis. The iBiopsy® system saves patients’ lives and is curative. Median Technologies’ optimism about the evolution of cancer treatments is driven by technology and artificial intelligence. AI is revolutionizing early cancer diagnosis and can also have a positive impact on the treatment of many other diseases.
Revolutionizing Cancer Diagnosis
Cellular Information from Traditional CT Images
In a groundbreaking development, iBiopsy® Lung Cancer Screening Software as Medical Device has succeeded in extracting cellular information from traditional CT images, which is not visible in the image. By getting the ground truth in their study and correlating their information with the patients’ actual medical history over 20 years, iBiopsy® was able to detect the development of cancer early on.
Preventive Diagnosis
This breakthrough discovery is crucial as it means that through a simple non-invasive scan, a large-scale screening plan can be set up, making preventive diagnosis possible for cancer. A simple CT scan could determine whether a patient has cancer or not, potentially saving millions of lives worldwide. The possibilities for early diagnosis using AI and innovative technology have never been more exciting, and the future looks brighter than ever before.
Don’t miss interesting posts on Famousbio
